CN105315338A - LDV-modified [beta]-carboline, and preparation, nano structure, activity and application thereof - Google Patents
LDV-modified [beta]-carboline, and preparation, nano structure, activity and application thereof Download PDFInfo
- Publication number
- CN105315338A CN105315338A CN201410261582.9A CN201410261582A CN105315338A CN 105315338 A CN105315338 A CN 105315338A CN 201410261582 A CN201410261582 A CN 201410261582A CN 105315338 A CN105315338 A CN 105315338A
- Authority
- CN
- China
- Prior art keywords
- carboline
- hydroxyl
- asp
- val
- leu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses 1-(4-hydroxyl-3-methoxycarbonylphenyl)-[beta]-carboline-3-formyl-Leu-Asp-Val represented as the following formula, wherein a standard abbreviation of the Leu-Asp-Val is LDV. The invention also discloses a preparation method, a nano structure and an anti-tumor effect of the compound, discloses the effect of the compound of inhibiting adhesion, invasion and migration of tumor cells and further discloses anti-inflammation and anti-thrombus effects of the compound and discloses the applications of the compound in medicine.
Description
Technical field
The present invention relates to 1-(4-hydroxyl-3-methoxycarbonyl phenyl)-β-carboline-3-formyl-Leu-Asp-Val of structure below.Relate to its preparation method, relate to its nanostructure, relate to its inside and outside antitumor action, relate to the effect that its antitumor cell adheres to, attacks and move, relate to its anti-inflammatory and antithrombotic effect further.Thus the present invention relates to it and preparing antitumor drug, prepare antitumor cell migration, adhere to and invasion and attack medicine, prepare anti-inflammatory medicaments and prepare the application in antithrombotic reagent.The invention belongs to biomedicine field.
Technical background
The health of the malignant tumour serious threat mankind.Except self is severe to the prognosis of tumour patient, the inflammation of Complicated by Malignancy, thrombus and transfer worsen the prognosis of patient further.Such as, the malignant tumor patient more than more than 90% is all die from metastases.Metastases depends on 4 factors: 1) tumor cell surface forms microthrombus, escapes macrophage phagocytic, moves to far-end by blood circulation; 2) tumor cell adhesion of far-end is moved to vessel wall; 3) cell adhesion enters healthy tissues to the tumour cell of vessel wall by attacking out blood vessel; 4) inflammation makes the tumour cell entering healthy tissues grow into the nascent tumor of transfer.
Adhere to and invasion and attack effect, so curative effect is undesirable because existing antitumor drug does not possess the migration of anti-inflammatory, antithrombotic and antitumor cell.It is clinical active demand that invention has antitumor, that anti-inflammatory, antithrombotic and antitumor cell move adhesion and invasion and attack medicine simultaneously.
RGD tetrapeptide, namely RGDS, RGDF and RGDV are integrin alphas
vβ
3blocker, there is antithrombotic and Anti cell adhesion active.Leu-Asp-Val (LDV) then can specific effect in integrin alpha
4β
1, applicant finds that it can adhere to and infiltrate by inhibition tumor cell when concentration is 1 μM.Applicant is once them and oestrogenic hormon coupling, and preparation does not have the osteoporosis agent of blood coagulation side effect.Applicant once prepared efficient antithrombotic agent them and the coupling of tetrahydro-beta-carboline-3-carboxylic acid.Applicant is also once with the β-carboline-3-carboxylic acid that amino acid modified tetrahydro-beta-carboline-3-carboxylic acid, β-carboline-3-carboxylic acid and 1-position replace, and the β-carboline-3-carboxylic acid of the tetrahydro-beta-carboline-3-carboxylic acid or the replacement of 1-position that comprise the replacement of 1-position prepares efficient antithrombotic agent or antineoplastic agent.Here is the representative of the structure type that contriver creates.Although contriver has paid large quantity research energy, screen hundreds of compound, never there is antitumor, anti-inflammatory, antithrombotic and inhibiting effect on tumor metastasis compound simultaneously.
Contriver is in the analysis structure of hundreds of compound and the basis of activity change, recognize Leu-Asp-Val and 1-(4-hydroxyl-3-methoxycarbonyl phenyl)-β-carboline-3-carboxylic acid coupling, 1-(4-hydroxyl-3-methoxycarbonyl phenyl)-β-carboline-3-formyl-Leu-Asp-Val of formation can have antitumor, anti-inflammatory, antithrombotic and antitumor cell migration simultaneously and adhere to and invasion and attack effect.Based on this understanding, inventors herein propose the present invention.
Summary of the invention
First content of the present invention is to provide 1-(4-hydroxyl-3-methoxycarbonyl phenyl)-β-carboline-3-formyl-Leu-Asp-Val of structure below.
Second content of the present invention is to provide the preparation method of 1-(4-hydroxyl-3-methoxycarbonyl phenyl)-β-carboline-3-formyl-Leu-Asp-Val, and the method comprises:
(1) under the vitriol oil exists, 5-formylsalicylic acid is 90 DEG C, microwave reaction 2h in methyl alcohol, generates 5-formylsalicylic acid methyl esters;
(2) under the existence of polyphosphoric acid, L-Trp and phenylcarbinol reaction, generate L-Trp benzyl ester;
(3) under trifluoracetic acid exists, in methylene dichloride, 5-formylsalicylic acid and the ester condensation of L-Trp benzyl are 1-(4-hydroxyl-3-methoxycarbonyl phenyl)-1,2,3,4-tetrahydro-beta-carboline-3-benzyl carboxylates;
(4) 2,3-bis-chloro-5,6-dinitrile-1, under the existence of 4-benzoquinones (DDQ), 1-(4-hydroxyl-3-methoxycarbonyl phenyl)-1,2,3,4-tetrahydro-beta-carboline-3-benzyl carboxylate is oxidized to 1-(4-hydroxyl-3-methoxycarbonyl phenyl)-β-carboline-3-benzyl carboxylate in tetrahydrofuran (THF) (THF);
(5) at Pd/C and H
2under existence, in methyl alcohol, the reaction of 1-(4-hydroxyl-3-methoxycarbonyl phenyl)-β-carboline-3-benzyl carboxylate generates 1-(4-hydroxyl-3-methoxycarbonyl phenyl)-β-carboline-3-carboxylic acid;
(6) adopt progressively condensation method, under DCC and HOBt exists, react in dry THF, obtain full guard peptide sequence Boc-Leu-Asp (OBzl)-Val-OBzl;
(7) under ice bath hydrogenchloride ethyl acetate solution (4M) in, full guard peptide sequence Boc-Leu-Asp (OBzl)-Val-OBzl removes Boc and obtains Leu-Asp (OBzl)-Val-OBzl;
(8) under DCC and HOBt exists, 1-(4-hydroxyl-3-methoxycarbonyl phenyl)-β-carboline-3-carboxylic acid is 1-(4-hydroxyl-3-methoxycarbonyl phenyl)-β-carboline-3-formyl-Leu-Asp (OBzl)-Val-OBzl with Leu-Asp (OBzl)-Val-OBzl condensation in anhydrous THF;
(9) at Pd/C and H
2under existence, in methyl alcohol, compound 1-(4-hydroxyl-3-methoxycarbonyl phenyl)-β-carboline-3-formyl-Leu-Asp (OBzl)-Val-OBzl is obtained by reacting compound 1-(4-hydroxyl-3-methoxycarbonyl phenyl)-β-carboline-3-formyl-Leu-Asp-Val.
3rd content of the present invention is the nanostructure measuring 1-(4-hydroxyl-3-methoxycarbonyl phenyl)-β-carboline-3-formyl-Leu-Asp-Val.
4th content of the present invention evaluates the effect of 1-(4-hydroxyl-3-methoxycarbonyl phenyl)-β-carboline-3-formyl-Leu-Asp-Val extracorporeal suppression tumor cell propagation.
5th content of the present invention is that assessing compound 1-(4-hydroxyl-3-methoxycarbonyl phenyl)-β-carboline-3-formyl-LDV is to the restraining effect of lotus s180 mice tumors grew.
6th content of the present invention is the effect evaluated 1-(4-hydroxyl-3-methoxycarbonyl phenyl)-β-carboline-3-formyl-Leu-Asp-Val extracorporeal suppression tumor cell adhesion, invasion and attack and move.
7th content of the present invention evaluates anti-inflammatory action in 1-(4-hydroxyl-3-methoxycarbonyl phenyl)-β-carboline-3-formyl-Leu-Asp-Val body.
8th content of the present invention evaluates anti thrombotic action in the In Vitro Anti platelet aggregation of 1-(4-hydroxyl-3-methoxycarbonyl phenyl)-β-carboline-3-formyl-Leu-Asp-Val and body.
Accompanying drawing explanation
Fig. 1. the structure type representative of the antithrombotic that contriver creates or active compound for anti tumor, in formula, AA is L-amino acid or glycine.
Fig. 2. the synthetic route .i of compound 5) CH
3oH, dense H
2sO
4, 90 DEG C, microwave; Ii) polyphosphoric acid, phenylcarbinol, oil bath 75 DEG C; Iii) CH
2cl
2, TFA; Iv) THF, DDQ; V) CH
3oH, Pd/C, H
2; Vi) DCC, HOBt, NMM, THF; Vii) hydrogenchloride/ethyl acetate solution (4M).
Fig. 3. compound 5 is in pure water solution 1 × 10
-7transmission electron microscope photo under M concentration.
Fig. 4. compound 5 acts on the cell viability figure (n=3) of tumour cell.
Embodiment
In order to set forth the present invention further, provide a series of embodiment below.These embodiments are illustrative completely, and they are only used for being specifically described the present invention, not should be understood to limitation of the present invention.
Embodiment 1 prepares 5-formylsalicylic acid methyl esters
Take 1.660g (10.0mmol) 5-formylsalicylic acid in microwave reaction tank, add 25mL methyl alcohol and the dense H of 1mL
2sO
490 DEG C of reaction 2h in microwave reactor, TLC monitoring is utilized to disappear to raw material spot, after stopped reaction is down to room temperature, reaction solution is transferred in 100mL eggplant-shape bottle, with strong aqua adjust pH to 7-8, reaction solution is evaporated to after doing, add a large amount of acetic acid ethyl dissolution, ethyl acetate layer uses saturated NaHCO successively
3, saturated NaCl respectively washes three times, then uses anhydrous Na
2sO
4dry 2h, filter, be evaporated to dry, namely having crystal to separate out in left at room temperature over night, obtain 1.635g (90.8%) target compound, is faint yellow needle-like crystal.ESI-MS(m/e)：181[M+H]
+。
Embodiment 2 prepares L-Trp benzyl ester
Take 15.0g (44.4mmol) polyphosphoric acid in 500mL eggplant-shape bottle, add 80mL phenylcarbinol, it is made to dissolve in oil bath 50 DEG C, after solution temperature rises to 75 DEG C, taking 10g (49.0mmol) L-Trp adds wherein, 48h is reacted at 75 DEG C, TLC monitoring is utilized to disappear to raw material spot, after stopped reaction cooling, in reaction flask, 400mL anhydrous diethyl ether is poured under ice bath stirs, now adularescent solid is separated out, stirring spend the night after by it filtration, white solid 200mL ethyl acetate and 10mL aqueous suspension, about adjusting solution ph to 8 with triethylamine, solution becomes clarification shape, leave standstill separatory, the ester layer be separated is used saturated NaHCO successively
3, saturated NaCl respectively washes three times, ethyl acetate layer anhydrous Na
2sO
4dry 2h, filter, be evaporated to dry, obtaining 12.85g (89.2%) target compound, is white solid.ESI-MS(m/e)：295[M+H]
+。
Embodiment 3 prepares 1-(4-hydroxyl-3-methoxycarbonyl phenyl)-1,2,3,4-tetrahydro-beta-carboline-3-benzyl carboxylates (1)
100mLCH is added in 250mL eggplant-shape bottle
2cl
2and 10mLTFA, 11.76g (40.0mmol) L-Trp benzyl ester is taken and 7.92g (44.0mmol) 5-formylsalicylic acid methyl esters adds wherein after stirring, after several minutes, reaction solution becomes blush, after 2 days, reaction solution becomes black, strong aqua is slowly dripped by reaction solution adjust pH to 8 under ice bath stirs, reaction solution is left standstill separatory, by separation of C H
2cl
2layer uses saturated NaHCO successively
3, saturated NaCl respectively washes three times, CH
2cl
2layer anhydrous Na
2sO
4dry 2h, filter, be evaporated to dry, obtaining 14.59g (80%) target compound, is yellow solid.ESI-MS(m/e)：457[M+H]
+。
Embodiment 4 prepares 1-(4-hydroxyl-3-methoxycarbonyl phenyl)-β-carboline-3-benzyl carboxylate (2)
Take 1-(4-hydroxyl-3-methoxycarbonyl phenyl)-1,2,3,4-tetrahydro-beta-carboline-3-benzyl carboxylate 4.56g (10.0mmol), in 250mL eggplant-shape bottle, dissolves by dry THF, adds DDQ4.54g (20.0mmol), after several minutes, reaction solution becomes muddy, react completely after 4h, filter, leach solid and use saturated NaHCO successively
3, methyl alcohol, ether wash, filter, obtaining 3.75g (82.7%) target compound, is pale solid.ESI-MS(m/e)：453[M+H]
+；Mp：190.4-191.0℃.
1HNMR(300MHz，DMSO)：δ/ppm＝8.87(s，1H)，8.42(m，2H)，8.10(dd，J＝2.1Hz，J＝2.1Hz，1H)，7.69(d，J＝8.1Hz，1H)，7.57(m，3H)，7.37(m，3H)，7.04(d，J＝6.3Hz)，5.46(s，1H)，3.88(s，3H).
13CNMR(75MHz，DMSO)：δ/ppm＝169.28，165.93，142.35，137.07，135.13，131.75，129.30，128.98，128.47，128.41，122.40，121.73，120.62，116.54，114.71，66.39，52.47.Elem.Anal：C
27H
20N
2O
5.C，71.67；H，4.46；N，6.19。
Embodiment 5 prepares 1-(4-hydroxyl-3-methoxycarbonyl phenyl)-β-carboline-3-carboxylic acid (3)
2.26g (5.0mmol) 1-(4-hydroxyl-3-methoxycarbonyl phenyl)-β-carboline-3-benzyl carboxylate is suspended in 120mL methyl alcohol, add 400mgPd/C, reaction solution first takes air away with vacuum pump, then passes into hydrogen, 3 times so repeatedly, react 2 days under room temperature, utilize TLC to monitor to disappear to raw material spot, natural filtration reaction solution, is evaporated to dry by reaction solution, obtaining 1.080g (59.7%) target compound, is yellow solid.ESI-MS(m/e)：361[M-H]
-；Mp：227.1-227.9℃.Elem.Anal：C
20H
14N
2O
5.C，66.30；H，3.89；N，7.73。
Embodiment 6 prepares Leu-Asp (OBzl)-Val-OBzl
1) preparation of Boc-Asp (OBzl)-Val-OBzl
1.62g (5.0mmol) Boc-Asp (OBzl) is suspended in 20mL dry THF, in solution, 0.68g (5.0mmol) HOBt is added under stirring at room temperature, ice bath adds 1.133g (5.5mmol) DCC under stirring, obtain reaction solution I, stir 30 minutes under ice bath.1.90g (5.0mmol) Val-OBzl is suspended in 20mL dry THF, then adds NMM gradually, regulate pH to 8-9, obtain reaction solution II.Reaction solution II is added in reaction solution I, first under ice bath, stir 1h, then in stirring at room temperature, TLC monitoring disappears to raw material point.Aftertreatment: filtration under diminished pressure removing DCU, filtrate reduced in volume is removed THF, and residue 150mLEA dissolves, and the solution obtained is placed in 250mL separating funnel, uses 5%KHSO successively
4the aqueous solution is washed and is respectively washed 3 times with the saturated NaCl aqueous solution, EA layer anhydrous Na
2sO
4dry 30min, filtration under diminished pressure, filtrate reduced in volume is to dry, and obtaining 2.48g (97%) title compound, is colorless solid.TLC condition: CH
2cl
2/ CH
3oH, 20: 1, R
f=0.38.ESI-MS (m/e): 513 [M+H]
+.
2) preparation of Asp (OBzl)-Val-OBzl
2.05g (4.0mmol) Boc-Asp (OBzl)-Val-OBzl is placed in 50mg eggplant bottle, ice bath stirs the lower slow 20mL4NHCl/EA solution that drips in reaction flask, add drying tube, ice bath stirs lower reaction TLC monitoring raw material point disappearance after 2 hours, termination reaction.Aftertreatment: under stirring with water pump by reaction solution decompressing and extracting, add EA dissolve after again use water pump decompressing and extracting, in triplicate; Leave standstill after adding the abundant suspendible of anhydrous diethyl ether, pour out ether, drain product, in triplicate, obtaining 1.74g (97%) title compound, is faint yellow solid.TLC condition: CH
2cl
2/ CH
3oH, 20: 1.ESI-MS (m/e): 413 [M+H]
+.
3) preparation of Boc-Leu-Asp (OBzl)-Val-OBzl
Obtaining 1.79g (82%) title compound by the preparation method of Boc-Asp (OBzl)-Val-OBzl by 0.81g (3.5mmol) Boc-Leu and 1.57g (3.5mmol) Asp (OBzl)-VaI-OBzl, is colorless solid.TLC condition: PE/EA, 3: 1, R
f=0.32.ESI-MS (m/e): 626 [M+H]
+.
4) preparation of Leu-Asp (OBzl)-Val-OBzl
Obtaining 1.21g (98%) title compound by the preparation method of Asp (OBzl)-Val-OBzl by 1.38g (2.2mmol) Boc-Leu-Asp (OBzl)-Val-OBzl, is colorless solid.TLC condition: PE/EA, 3: 1.ESI-MS (m/e): 526 [M+H]
+.
Embodiment 7 prepares 1-(4-hydroxyl-3-methoxycarbonyl phenyl)-β-carboline-3-formyl-Leu-Asp-Val (5)
1) preparation of 1-(4-hydroxyl-3-methoxycarbonyl phenyl)-β-carboline-3-formyl-Leu-Asp (OBzl)-Val-OBzl (4)
Obtaining 0.69g (78.9%) title compound by the preparation method of Boc-Asp (OBzl)-Val-OBzl by 0.36g (1.0mmol) 1-(4-hydroxyl-3-methoxycarbonyl phenyl)-β-carboline-3-carboxylic acid (3) and 0.56g (1.0mmol) Leu-Asp (OBzl)-Val-OBzl, is faint yellow solid.TLC condition: PE/Ace/HAc, 1.5: 1: 0.1, R
f=0.39.ESI-MS (m/e): 870 [M+H]
+.
1hNMR (300MHz, DMSO-d6): δ/ppm=11.92 (s, 1H), 10.76 (s, 1H), 8.83 (s, 1H), 8.61 (dd, J=6.9Hz, J=2.1Hz, 2H), 8.46 (d, J=2.1Hz, 1H), 8.40 (d, J=8.1Hz, 1H), 8.22 (dd, J=8.7Hz, J=2.4Hz, 1H), 8.07 (d, J=8.1Hz, 1H), 7.69 (d, J=8.1Hz, 1H), 7.61 (t, J=7.5Hz, 1H), 7.28 (m, 12H), 5.11 (d, J=5.4Hz, 2H), 5.05 (dd, J=4.2Hz, 2H), 4.72 (m, 1H), 4.21 (dd, J=8.1Hz, J=6.3Hz, 1H), 3.95 (s, 3H), 2.8l (dd, J=16.5Hz, J=5.1Hz, 1H), 2.65 (dd, J=16.2Hz, J=9Hz, 1H), 2.01 (m, 1H), 1.66 (m, 1H), 0.94 (dd, J=11.7Hz, J=9Hz, 6H), 0.83 (dd, J=6.6Hz, J=5.1Hz, 6H) .Elem.Anal:C
49h
51n
5o
10.C, 67.65, H, 5.91, N, 8.05.
2) preparation of 1-(4-hydroxyl-3-methoxycarbonyl phenyl)-β-carboline-3-formyl-Leu-Asp-Val (5)
By 0.69g (0.79mmol) 1-, (4-hydroxyl-3-methoxycarbonyl phenyl)-β-carboline-3-formyl-Leu-Asp (OBzl)-Val-OBzl is dissolved in 15mL methyl alcohol, 120mgPd/C is added under stirring at room temperature, use threeway ligation bottle and hydrogen gas bag, reaction solution first takes air away with vacuum pump, then hydrogen is passed into, so 3 times repeatedly, 48h is reacted under stirring at room temperature, TLC monitoring is utilized to disappear to raw material spot, filtration under diminished pressure reaction solution, being evaporated to by reaction solution dry, obtaining 0.312g (57.2%) target compound, is yellow solid.TLC condition: CH
2cl
2/ CH
3oH/HAc, 2.5: 0.25: 0.1, R
f=0.41.HPLC: moving phase (chromatogram acetonitrile/ultrapure water, 0min, 20: 80, 2min, 25: 75, 5min, 30: 70, 8min, 35: 65, 10min, 40: 60, 12min, 70: 30, 13min, 90: 10, 30min, 90: 10), retention time 14.71min, purity 99.0%.ESI-MS (m/e): 688 [M-H]
-dEG C .Mp=177.0-171.0.
(c=0.34, CH
3oH) .IR (KBr): 3327.21,2958.80,2935.66,2873.94,1718.58,1676.14,1525.69,1492.90,1448.54,1247.94,1213.23,744.52cm
-1.
1hNMR (300MHz, DMSO-d6): δ/ppm=12.01 (s, 1H), 10.76 (s, 1H), 8.82 (s, 1H), 8.61 (dd, J=7.2Hz, J=1.8Hz, 2H), 8.46 (d, J=2.4Hz, 1H), 8.40 (d, J=8.1Hz, 1H), 8.22 (dd, J=8.7Hz, J=2.4Hz, 1H), 7.69 (d, J=8.1Hz, 1H), 7.61 (t, J=8.4Hz, 1H), 7.35 (m, 2H), 4.72 (m, 2H), 4.10 (dd, J=8.1Hz, J=5.1Hz, 1H), 3.96 (s, 3H), 2.73 (dd, J=12.9Hz, J=5.7Hz, 1H), 2.54 (d, J=8.4Hz, 1H), 2.03 (m, 1H), 1.66 (m, 3H), 0.94 (dd, J=12.3Hz, J=6.0Hz, 6H), 0.83 (dd, J=6.6Hz, J=3.6Hz, 6H) .Elem.Anal:C
35h
39n
5o
10.C, 60.95, H, 5.70, N, 10.15.
Experimental example 1 measures the transmission electron microscope photo of compound 5
By compound 5 according to 1 × 10
-7the pure water solution of the concentration configuration compound of M, is layered on uniformly on copper mesh, observes the self-assembly property of compound under transmission electron microscope (TEM, JEM-1230, JEOL).The photo obtained is as Fig. 3.Result shows, compound 5 all can form nano particle in water, and diameter is between 45-180nm.
Experimental example 2 measures the cytotoxicity of compound 5 pairs of tumour cells
1) substratum of compound 5 of the present invention containing 0.1%DMSO is mixed with desired concn.
2) tumour cell of experiment is HepG
2(human liver cell cancer cells), HL60 (human promyelocytic leukemia), Bel-7402 (human liver cancer cell), HT-29 (human colon cancer cell), HeLa (human cervical carcinoma cell), A549 (human lung carcinoma cell), S180 (mouse ascites oncocyte) and HCCLM3 (people's height transfer liver cancer cell).
3) experimental technique HL-60, HT-29, Bel-7402, A549 and S180 cell selects RPMI-1640 substratum; HepG
2, HeLa and HCCLM3 cell selects DMEM substratum.In substratum all containing 10% through the foetal calf serum and 1 × 10 of deactivation
5u/L penicillin and 100mg/L Streptomycin sulphate.
Attached cell HepG2, the cultivation of HT-29, Bel-7402, A549, HeLa, HCCLM3 and half attached cell S180: respectively that growth conditions is good, is in the cell of logarithmic phase with 3 × 10
4the density of individual/mL is inoculated in 96 orifice plates, and every hole 100 μ L, is placed in 37 DEG C and 5%CO
2cell incubation case in cultivate 4 hours, then add by the concentration gradient preset the solution that the compound 5 through sterilising treatment is mixed with the substratum containing 0.1%DMSO, every hole 25 μ L, control group adds the solvent of isopyknic sample dissolution.Continue cultivation after 48 hours, every hole adds the MTT solution that 25 μ L concentration are 5mg/mL, is placed in 37 DEG C and 5%CO
2cell incubation case in cultivate 4 hours.After careful removing supernatant liquor, every hole adds the DMSO of 100 μ L, and about 10min dissolve purple of vibrating residue (first a ceremonial jade-ladle, used in libation), detects O.D. (absorbancy) value immediately in microplate reader, and wavelength is 570nm.
The cultivation of suspension cell HL60: respectively that growth conditions is good, is in the cell of logarithmic phase with 5 × 10
4the density of individual/mL is inoculated in 96 orifice plates, every hole 100 μ L, then adds by the concentration gradient preset the solution that the compound 5 through sterilising treatment is mixed with the substratum containing 0.1%DMSO, every hole 25 μ L, control group adds the solvent of isopyknic sample dissolution, is placed in 37 DEG C and 5%CO
2cell incubation case in cultivate 48 hours.Every hole adds the MTT solution that 25 μ L concentration are 5mg/mL, and continuing the condition that is placed in is 37 DEG C and 5%CO
2cell incubation case in cultivate 4 hours.The centrifugal 10min of 2500rpm, careful sucking-off supernatant liquor, every hole adds 100 μ LDMSO, and about 10min dissolve purple of vibrating residue (first a ceremonial jade-ladle, used in libation), detects O.D. (absorbancy) value immediately in microplate reader, and wavelength is 570nm.
The activity of compound 5 inhibition tumor cell propagation under each concentration is obtained by following formula:
Cell proliferation (%)=(the average O.D. value of compound 5 groups average O.D. value/control group) × 100%, experiment repetition 3 times, maps to drug level with cell proliferation, obtains IC by graphing method
s0(half effective inhibition concentration) value.
4) the results are shown in Figure 4.Result shows,
In vitro in cytotoxicity test, have rated compound 5 only the high density of 100 and 200 μMs to Bel-7402, HepG
2, HL60, HT-29, HeLa, S180, A549 and HCCLM3 etc. 8 strain tumour cell show weak cytotoxicity.
The anti-tumor in vivo of experimental example 3 assessing compound 5 is active
1) physiological saline solution of compound 5 tween 80 of the present invention, Zorubicin physiological saline solution is as positive control, and the physiological saline of tween 80 is as negative control;
2) the equal gastric infusion of the physiological saline of compound 5 and tween 80, the dosage of compound 5 is 10nmol/kg, and the dosage of the physiological saline of tween 80 is 0.2mL/20g, successive administration 7 days, altogether administration 7 times; Zorubicin intraperitoneal administration, dosage is 2 μm of ol/kg, successive administration 7 days, altogether administration 7 times.
3) laboratory animal is ICR male mice (cleaning grade), body weight 20 ± 2g, often organizes 12 mouse.
4) knurl source is mouse S 180 sarcoma, purchased from Department Of Medicine, Peking University's animal experimental center, and maintenance of going down to posterity voluntarily.
5) extract and inoculate eugonic S180 ascitic tumor knurl liquid under animal model and treatment aseptic condition, the liquid of (1: 2) is become fully to mix with normal saline dilution, by freshly prepared 0.2% Trypan Blue of tumor cell suspension, by white blood cell count(WBC) method counting after mixing, contaminate blue person for dead cell, tinter is not viable cell, and is calculated as follows cell concn and cell survival rate.
Viable count/4 × 10 in the block plaid of cell concn=4
4× extension rate=cell count/mL
Cell survival rate=viable count/(viable count+dead cell number) × 100%
Knurl liquid homogenate method survival rate being greater than 90% is prepared into 2.0 × 10
7the cell suspension of individual/mL, in the subcutaneous vaccination of mouse armpit, 0.2mL/ only, manufactures S180 tumor-bearing mice.After tumor inoculation 24h, treatment group mouse oral administration of compound every day 5, dosage is 10nmol/kg.The physiological saline of naive mice oral 0.2mL tween 80 every day.Positive controls mouse abdominal injection every day Zorubicin, dosage is 2 μm of ol/kg.Experiment proceeds to the 8th day, claim Mouse Weight, etherization, de-cervical vertebra puts to death mouse, then fixes the right armpit tumor location of mouse with tweezers, cuts off skin, expose tumour, blunt separation, weighs, and is calculated as follows tumour inhibiting rate: the average knurl of tumour inhibiting rate %=(the average knurl of negative control group heavy-the average knurl weight of compound 5 groups)/negative control group heavy × 100%.Experimental data adopts t inspection and variance analysis, knurl heavy with
represent.The results are shown in Table 1.As can be seen from Table 1, under the oral dosage of 10nmol/kg, the knurl of compound 5 treatment group mouse weighs tool significant difference compared with physiological saline group, does not have significant difference compared with Zorubicin group.Visible, the effective dose of compound 5 is lower than Zorubicin 200 times.
The anti-tumor in vivo of table 1 compound 5 is active
N=12; A) with physiological saline group than p < 0.01, with Zorubicin group than p > 0.05.
The extracorporeal anti-tumor cell adhesion activity of experimental example 4 assessing compound 3 and 5
1) the DMEM substratum of compound 3 and 5 containing 0.1%DMSO is mixed with the solution that concentration is 100nM.
2) cell is HCCLM3 (high-transfer human liver cancer cell).
3) Fn (people's fibronectin).
4) experimental technique
With PBS, Fn is mixed with the solution that concentration is 100 μ g/mL, adds in 96 well culture plates by 100 μ L/ holes, culture plate is placed in 4 DEG C of refrigerator overnight.Next day, absorb and do not wrap by Fn solution, wash 1 time with PBS, every hole adds the PBS solution 30 μ L shrouding containing 2%FBS, at 37 DEG C and 5%CO
2incubator in hatch 3 hours, discard each hole solution.By good for growth conditions, be in the HCCLM3 cell of logarithmic phase with 5 × 10
4the density of individual/mL is inoculated in bag by 96 orifice plates of Fn, and every hole 100 μ L, adds the solution of 25 μ L compounds 3 or 5 simultaneously, makes its final concentration be 20nM, at 37 DEG C and 5%CO
2cultivate 2 hours in incubator, wash away the cell do not adhered to PBS, after discarding PBS, every hole adds the MTT solution that 25 μ L concentration are 5mg/mL, is placed in 37 DEG C and 5%CO
2hatch 4 hours in incubator, after careful removing supernatant liquor, every hole adds 100 μ LDMSO, and vibrate about 10min dissolution precipitation, detects O.D. (absorbancy) value immediately under microplate reader 570nm wavelength.The calculation formula of adherence inhibition rate is as follows: adherence inhibition rate (%)=[1-(the OD value of the OD value/blank group cell of compound 5 groups of cells)] × 100%; Experimental data statistics all adopts t inspection and variance analysis, and adherence inhibition rate represents with mean value ± SD.
5) the results are shown in Table 2.As can be seen from Table 2, compound 5 obviously suppresses HCCLM3 cell and FN to adhere under 20nM concentration, and adherence inhibition rate is 24.2%.Suppress SACC-LM cell to be compared with in the of 1 μM with the effective concentration of ECM and platelet adhesion reaction with LPNISKP, the effective concentration of compound 5 reduces 50 times.
The extracorporeal anti-tumor cell adhesion activity of table 2 compound 5
n＝3。
The extracorporeal anti-tumor cell-invasive activity of experimental example 5 assessing compound 3 and 5
1) the DMEM substratum of compound 3 and 5 containing 0.1%DMSO is mixed with the solution that concentration is 100nM.
2) cell is HCCLM3 (high-transfer human liver cancer cell).
3) matrigel is matrigel.
4) experimental technique
The frozen matrigel matrigel4 DEG C in-20 DEG C of refrigerators is spent the night, liquefy; Get 720 μ L plasma-free DMEM medium, add 180 μ LMatrigel, mixing, room on the polycarbonate membrane being added to Transwell cell, 100 μ L/, put into 37 DEG C and 5%CO
25h is hatched in incubator.Absorb residual liquid in cell, every hole adds 50 μ LDMEM substratum, 37 DEG C and 5%CO
230min is hatched in incubator.
After HCCLM3 cell dissociation, wash 3 times with plasma-free DMEM medium, counting, be made into cell suspension, density is 5 × 10
5individual/mL.Every hole adds 100 μ L cell suspensions, adds the solution that 25 μ L add 25 μ L compounds 3 or 5 simultaneously simultaneously, makes its final concentration be 20nM.Blank adds the solution that 25 μ L prepare containing the DMEM substratum of 0.1%DMSO.Lower room adds 600 μ L plasma-free DMEM medium, at 37 DEG C and 5%CO
2cultivate 48 hours in incubator.
Wipe the cell of matrigel and upper indoor with cotton swab after, with the paraformaldehyde fixed cell 30min of 4%.Absorb stationary liquid, wash 3 times with PBS, with the Viola crystallina dye liquor dyeing 30min of 0.1%.Absorb staining fluid, wash 3 times with PBS.
Choose 9 roughly the same visuals field at each cell to observe, take pictures, counting.Experimental data statistics all adopts t inspection and variance analysis, and the cell count of invasion and attack represents with mean value ± SD.
5) the results are shown in Table 3.Can find out, under 20nM concentration, compound 3 is compared with blank group, and the cell count that invasion and attack occur significantly reduces, and illustrates that compound 3 has the effect of obvious anti-HCCLM3 cell invasion under this condition.It can also be seen that, under 20nM concentration, compound 5 is compared with compound 3, and the cell count that invasion and attack occur also significantly reduces, and illustrates that the effect of compound 5 anti-HCCLM3 cell invasion is obviously than compound the last 3 under this condition.Suppress the effective concentration of SACC-LM cell invasion to be compared with in the of 1 μM with LDV, the effective concentration of compound 5 reduces 50 times.
The extracorporeal anti-tumor cell-invasive activity of table 3 compound 5
N=9; A) with blank group and compound 3 groups than p < 0.01; B) with blank group than p < 0.01.
The extracorporeal anti-tumor cell migration of experimental example 6 assessing compound 3 and 5 is active
1) the DMEM substratum of compound 3 and 5 containing 0.1%DMSO is mixed with the solution that concentration is 100nM.
2) cell is HCCLM3 (high-transfer human liver cancer cell).
3) experimental technique
After HCCLM3 cell dissociation, wash 3 times with plasma-free DMEM medium, counting, be made into cell suspension, density is 2 × 10
6individual/mL.Every hole adds 100 μ L cell suspensions, adds the solution that 25 μ L add 25 μ L compounds 3 or 5 simultaneously simultaneously, makes its final concentration be 20nM.Blank adds the solution that 25 μ L prepare containing the DMEM substratum of 0.1%DMSO.Lower room adds 600 μ L plasma-free DMEM medium, at 37 DEG C and 5%CO
2cultivate 6 hours in incubator.
Wipe the cell of matrigel and upper indoor with cotton swab after, with the paraformaldehyde fixed cell 30min of 4%.Absorb stationary liquid, wash 3 times with PBS, with the Viola crystallina dye liquor dyeing 30min of 0.1%.Absorb staining fluid, wash 3 times with PBS.
Choose 9 roughly the same visuals field at each cell to observe, take pictures, counting.Experimental data statistics all adopts t inspection and variance analysis, and the cell count of invasion and attack represents with mean value ± SD.
4) the results are shown in Table 4.Can find out, under 20nM concentration, compound 3 is compared with blank group, and the cell count that invasion and attack occur significantly reduces, and illustrates that compound 3 has the effect of obvious anti-HCCLM3 cell invasion under this condition.It can also be seen that, under 20nM concentration, compound 5 is compared with compound 3, and the cell count that invasion and attack occur also significantly reduces, and illustrates that the effect of compound 5 anti-HCCLM3 cell invasion is obviously than compound the last 3 under this condition.Suppress the effective concentration of SACC-LM cell invasion to be compared with in the of 1 μM with LDV, the effective concentration of compound 5 reduces 50 times.
The extracorporeal anti-tumor cell migration of table 4 compound 5 is active
N=9; A) with blank group and compound 3 groups than p < 0.01.
The interior anti-inflammatory activity of experimental example 7 assessing compound 5
1) experimental technique
18-22gICR male mice is divided into blank group, positive medication group and administration group at random, and tranquillization 1 day before mouse uses, operation room keeps room temp 22 DEG C, often organizes mouse 10.The left ear gabarit of single administration toward small white mouse after 30 minutes is coated with dimethylbenzene (0.03mL), is put to death by small white mouse cervical dislocation after 2 hours.By a left side for mouse, auris dextra is cut, and with the punch tool of diameter 7mm in the same position of two ears, gets circular auricle, weighs respectively, obtains the weight difference of two circle auricles as swelling.Swelling=former of left ear weight-auris dextra former weight.
2) medication and dosage
Gastric infusion.Blank is physiological saline, and dosage is 0.2mL/20g.Positive control is acetylsalicylic acid, and dosage is 1.11mmol/kg.The dosage of compound 5 is 10nmol/kg.
3) statistical method
Data statistics all adopts t to check and variance analysis, and swelling represents with mean value ± SDmg.
4) the results are shown in Table 5.Can find out, when dosage is 10nmol/kg, the mouse ear swelling degree of compound 5 treatment group has significant difference compared with NS group, illustrates that compound 5 can suppress mouse to be inflamed.There was no significant difference compared with the mouse ear swelling degree that when dosage is 10nmol/kg, mouse ear swelling degree and the dosage of compound 5 treatment group is the aspirin for treatment group of 1.11mmol/kg, illustrates that the anti-inflammatory activity of compound 5 is stronger than acetylsalicylic acid 111000 times.
The interior anti-inflammatory activity of table 5 compound 5a
N=12; A) with physiological saline group than p < 0.01 with acetylsalicylic acid group than p > 0.05.
The In Vitro Anti platelet aggregation of experimental example 8 compound 5 is evaluated
The In Vitro Anti platelet aggregation activity of experimental example 8 assessing compound 5a-c
1) arachidonic acid (AA) is platelet aggregation
2) SD male rat (cleaning grade), body weight 250 ± 20g, purchased from Beijing Vital River Experimental Animals Technology Co., Ltd..3) method
Rat gets blood with after the urethane anesthesia of 20% through carotid artery, adds Sodium Citrate (9: 1, the v/v) anti-freezing of 3.8%, 1mL Trisodium Citrate is added in 9mL whole blood, with the rotating speed of 1000r/min centrifugal 10 minutes, get supernatant, be platelet rich plasma (PRP); By remaining whole blood with the rotating speed of 3000r/min centrifugal 10 minutes, get supernatant, be platelet poor plasma (PPP).
Open platelet aggregation instrument, its system temperature is adjusted to 37 DEG C, adjusting rotary speed is 1000 turns, preheating 30min.Get a glass tubule, add 240 μ LPPP, put into groove instrument being marked with PPP.Get a glass tubule again, put into rotor, add 240 μ LPRP, put into groove instrument being marked with PRP.
Open program, click " runnewpatient ", input sample ID, while with mouse hit OK key, left hand presses the dark buttons of the side on platelet aggregation instrument, can see that the curve in recorder is rising, when curve rises to zero time, left hand unclamps dark buttons, now can see As time goes on, curve is movement steadily near baseline, retouches the hematoblastic accumulation process of meter in real time.
Physiological saline is blank.Treat that baseline stability walks out about 1 minute, use that micro sample adding appliance is disposable adds 5 μ L physiological saline, curve can be observed continue again slowly to move in time near baseline after the rising occurring moment, after curve is steady, use the disposable AA solution adding 5 μ L and prepare of micro sample adding appliance, curve can be observed suddenly decline after the rising occurring moment, illustrate that thrombocyte there occurs gathering under the induction of AA.When curve drops to a certain degree, there is plateau, show that hematoblastic gathering reaches maximum value, after curve is stable, the record MA of thrombocyte within 6 minutes (instrument calculates automatically), replication 6 times, tries to achieve the mean value of platelet aggregation rate under AA effect;
Compound 5 is administration group.Prepare the PRP that a pipe is new, as above method puts into instrument, treat that baseline stability walks out about 1 minute, use the disposable normal saline solution adding the compound 5a-c that 5 μ L prepare of micro sample adding appliance, curve can be observed continue again slowly to move in time near baseline after the rising occurring moment, after curve is steady, use the disposable AA solution adding 5 μ L and prepare of micro sample adding appliance, curve can be observed start to decline after the rising occurring moment, illustrate that thrombocyte there occurs gathering under AA effect, when curve drops to a certain degree, there is plateau, under showing this condition, hematoblastic gathering reaches maximum value, after curve is stable, the record MA of thrombocyte within 6 minutes (instrument calculates automatically), replication 6 times, try to achieve after adding medicine, the mean value of the lower platelet aggregation rate of AA effect,
Computerized compound is to the inhibiting rate of the platelet aggregation that AA induces as follows: inhibiting rate=(physiological saline group aggregation rate-administration group aggregation rate)/physiological saline group aggregation rate × 100%; Platelet aggregation-against rate represents with mean value ± SD.
4) the results are shown in Table 6.Can find out, the platelet aggregation that when concentration is 20nM, compound 5 can suppress AA to induce significantly.
Table 6 compound 5 In Vitro Anti platelet aggregation
N=3; A) with physiological saline group than p < 0.01.
Antithrombotic acitivity in the body of experimental example 9 assessing compound 5
1) experiment material
SD male rat (cleaning grade), body weight 200 ± 20g, purchased from Beijing Vital River Experimental Animals Technology Co., Ltd., is divided into 3 groups at random, often organizes 12 rats.Administering mode is gavage.Blank is physiological saline, and dosage is 0.6mL/200g; Positive control is acetylsalicylic acid, and dosage is 50 μm of ol/kg.The dosage of compound 5 is 10nmol/kg.
Experiment intubate is formed by 3 sections, middle segment length 8.0cm, internal diameter 0.3cm, two ends are identical polyethylene tube, long 10.0cm, internal diameter 0.1cm, external diameter 0.2cm, one end of this pipe pulls into point pipe (for inserting rat carotid artery or jugular vein), all uses the silicon ether silanization of 1% before the inwall use of 3 sections of pipes.The silk thread of the long 6.0cm weighed in advance is put into stage casing polyethylene extra heavy pipe, and the two ends of extra heavy pipe are nested with the non-drawing-down end of two polyethylene tubules respectively (wherein one section silk thread is pushed down 0.5mm fix).For subsequent use by filling heparin-saline solution (50IU/kg) in pipe by sharp pipe end with syringe.
2) model and treatment
Gavage gives the physiological saline that dosage is 0.6mL/200g, or dosage is the acetylsalicylic acid of 50 μm of ol/kg, or dosage is after the compound 30min of 10nmol/kg, by rat with 20% urethane solution (6mL/kg, i.p.) anaesthetize.Anesthetized rat dorsal position is fixed, isolate the left side external jugular vein of rat, proximal part and distal end penetrate surgical thread respectively, ligation distal end, the left external jugular vein exposed cuts an angle carefully, the non-line ball end point pipe of the intubate prepared is inserted the proximal part of left external jugular vein opening by angle, pushed the heparin-saline (50IU/kg) of correct amount by the sharp pipe of the other end with syringe, now syringe does not withdraw polyethylene tube, be separated right carotid, in proximal part folder bulldog clamp, proximal part and distal end penetrate surgical thread respectively, ligation distal end, right common carotid artery is being cut an angle carefully nearby from bulldog clamp.Extract syringe from the tip of polyethylene tube, the tip of polyethylene tube is inserted the proximal part of artery angle.The two ends of bypass duct all use 4 trumpeter's art suture ligatures to fix.Open bulldog clamp, make blood flow flow to jugular vein by bypass duct from carotid artery.From circulation time timing, take out from bypass duct after 15min and hang with the silk thread of thrombus, accurately weigh, the wet weight of thrombus that is of poor quality before and after silk thread represents with mean value ± SDmg.Data statistics all adopts t to check and variance analysis.
3) the results are shown in Table 7.Can find out, the wet weight of thrombus of compound 5 treatment group rat is significantly less than the wet weight of thrombus with saline rats, illustrates that compound 5 shows anti-arterial thrombus and generates active while neoplasm growth.
Antithrombotic acitivity in the body of table 7 compound 5
n=10; A) p < 0.01 is compared with NS group.
Claims (7)
1. 1-(4-hydroxyl-3-methoxycarbonyl phenyl)-β-carboline-3-formyl-Leu-Asp-Val of structure below.
2. the preparation method of 1-(4-hydroxyl-3-methoxycarbonyl phenyl)-β-carboline-3-formyl-Leu-Asp-Val of claim 1, the method is made up of following steps:
(1) under the vitriol oil exists, 5-formylsalicylic acid is 90 DEG C, microwave reaction 2h in methyl alcohol, generates 5-formylsalicylic acid methyl esters;
(2) under the existence of polyphosphoric acid, L-Trp and phenylcarbinol reaction, generate L-Trp benzyl ester;
(3) under trifluoracetic acid exists, in methylene dichloride, 5-formylsalicylic acid and the ester condensation of L-Trp benzyl are 1-(4-hydroxyl-3-methoxycarbonyl phenyl)-1,2,3,4-tetrahydro-beta-carboline-3-benzyl carboxylates;
(4) 2,3-bis-chloro-5,6-dinitrile-1, under the existence of 4-benzoquinones (DDQ), 1-(4-hydroxyl-3-methoxycarbonyl phenyl)-1,2,3,4-tetrahydro-beta-carboline-3-benzyl carboxylate is oxidized to 1-(4-hydroxyl-3-methoxycarbonyl phenyl)-β-carboline-3-benzyl carboxylate in tetrahydrofuran (THF) (THF);
(5) at Pd/C and H
2under existence, in methyl alcohol, the reaction of 1-(4-hydroxyl-3-methoxycarbonyl phenyl)-β-carboline-3-benzyl carboxylate generates 1-(4-hydroxyl-3-methoxycarbonyl phenyl)-β-carboline-3-carboxylic acid;
(6) adopt progressively condensation method, under DCC and HOBt exists, react in dry THF, obtain full guard peptide sequence Boc-Leu-Asp (OBzl)-Val-OBzl;
(7) under ice bath hydrogenchloride ethyl acetate solution (4M) in, full guard peptide sequence Boc-Leu-Asp (OBzl)-Val-OBzl removes Boc and obtains Leu-Asp (OBzl)-Val-OBzl;
(8) under DCC and HOBt exists, 1-(4-hydroxyl-3-methoxycarbonyl phenyl)-β-carboline-3-carboxylic acid is 1-(4-hydroxyl-3-methoxycarbonyl phenyl)-β-carboline-3-formyl-Boc-Leu-Asp (OBzl)-Val-OBzl with Boc-Leu-Asp (OBzl)-Val-OBzl condensation in anhydrous THF;
(9) at Pd/C and H
2under existence, in methyl alcohol, compound 1-(4-hydroxyl-3-methoxycarbonyl phenyl)-β-carboline-3-formyl-Leu-Asp (OBzl)-Val-OBzl is obtained by reacting compound 1-(4-hydroxyl-3-methoxycarbonyl phenyl)-β-carboline-3-formyl-Leu-Asp-Val.
3. the nanostructure of 1-(4-hydroxyl-3-methoxycarbonyl phenyl)-β-carboline-3-formyl-Leu-Asp-Val of claim 1.
4. 1-(4-hydroxyl-3-methoxycarbonyl phenyl)-β-carboline-3-formyl-Leu-Asp-Val of claim 1 is preparing the application in antitumor drug.
5. 1-(4-hydroxyl-3-methoxycarbonyl phenyl)-β-carboline-3-formyl-Leu-Asp-Val of claim 1 is preparing the application in antitumor cell migration adhesion and invasion and attack medicine.
6. 1-(4-hydroxyl-3-methoxycarbonyl phenyl)-β-carboline-3-formyl-Leu-Asp-Val of claim 1 is preparing the application in anti-inflammatory medicaments.
7. 1-(4-hydroxyl-3-methoxycarbonyl phenyl)-β-carboline-3-formyl-Leu-Asp-Val of claim 1 is preparing the application in antithrombotic reagent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410261582.9A CN105315338A (en) | 2014-06-11 | 2014-06-11 | LDV-modified [beta]-carboline, and preparation, nano structure, activity and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410261582.9A CN105315338A (en) | 2014-06-11 | 2014-06-11 | LDV-modified [beta]-carboline, and preparation, nano structure, activity and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105315338A true CN105315338A (en) | 2016-02-10 |
Family
ID=55243729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410261582.9A Pending CN105315338A (en) | 2014-06-11 | 2014-06-11 | LDV-modified [beta]-carboline, and preparation, nano structure, activity and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105315338A (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107459558A (en) * | 2016-06-03 | 2017-12-12 | 首都医科大学 | The pteridinylmethyl methylamino benzoyl Glu peptides of 2,4 diaminourea 6, it is synthesized, activity and application |
| CN107488211A (en) * | 2016-06-13 | 2017-12-19 | 首都医科大学 | Warfarin -4-O- acetyl-LDV, it is synthesized, activity and application |
| CN108976280A (en) * | 2017-05-30 | 2018-12-11 | 首都医科大学 | The amine-modified LDV of fat, synthesis, activity and application |
| CN108976282A (en) * | 2017-06-01 | 2018-12-11 | 首都医科大学 | The LDV derivative of fatty alcohol modification, synthesis, activity and application |
| CN108976283A (en) * | 2017-05-30 | 2018-12-11 | 首都医科大学 | 1,1- dihydroxymethyl-tetrahydro-beta-carboline -3- formyl-GLDV, synthesis, activity and application |
| CN108976281A (en) * | 2017-06-01 | 2018-12-11 | 首都医科大学 | The LDV derivative of fatty acid modifying, synthesis, activity and application |
| CN109111502A (en) * | 2017-06-23 | 2019-01-01 | 首都医科大学 | 1,1- dihydroxymethyl-tetrahydro-beta-carboline -3- formyl-GGPRP, synthesis, activity and application |
| CN110551176A (en) * | 2018-06-04 | 2019-12-10 | 首都医科大学 | LDV modified S, R-heptacyclic aldehyde, and synthesis, activity and application thereof |
| CN110577582A (en) * | 2018-06-08 | 2019-12-17 | 首都医科大学 | LDV modified heptacyclic aldehyde, synthesis, antithrombotic activity and application thereof |
| CN111995658A (en) * | 2019-05-27 | 2020-11-27 | 首都医科大学 | LDV (laser direct structuring) modified pentacyclic piperazinedione and preparation and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102241675A (en) * | 2010-05-14 | 2011-11-16 | 首都医科大学 | (1R,3S)-1-(4-hydroxyl-3-methoxycarboxyl)-1,2,3,4-tetrahydro-beta-carboline-3-formyl amino acid derivatives as well as preparation method and application thereof |
| CN103159828A (en) * | 2011-12-14 | 2013-06-19 | 首都医科大学 | 1-(4-hydroxy-3-methoxycarbonyl)-beta-carboline-3-formyl tryptophyl amino acid benzyl ester, and synthesis and application thereof |
-
2014
- 2014-06-11 CN CN201410261582.9A patent/CN105315338A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102241675A (en) * | 2010-05-14 | 2011-11-16 | 首都医科大学 | (1R,3S)-1-(4-hydroxyl-3-methoxycarboxyl)-1,2,3,4-tetrahydro-beta-carboline-3-formyl amino acid derivatives as well as preparation method and application thereof |
| CN103159828A (en) * | 2011-12-14 | 2013-06-19 | 首都医科大学 | 1-(4-hydroxy-3-methoxycarbonyl)-beta-carboline-3-formyl tryptophyl amino acid benzyl ester, and synthesis and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 何平均等: "抗肿瘤寡肽类药物研究进展", 《中国医药生物技术》 * |
Cited By (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107459558B (en) * | 2016-06-03 | 2021-02-12 | 首都医科大学 | 2, 4-diamino-6-pteridinylmethylaminobenzoyl-Glu-peptides, their synthesis, activity and use |
| CN107459558A (en) * | 2016-06-03 | 2017-12-12 | 首都医科大学 | The pteridinylmethyl methylamino benzoyl Glu peptides of 2,4 diaminourea 6, it is synthesized, activity and application |
| CN107488211A (en) * | 2016-06-13 | 2017-12-19 | 首都医科大学 | Warfarin -4-O- acetyl-LDV, it is synthesized, activity and application |
| CN107488211B (en) * | 2016-06-13 | 2021-03-30 | 首都医科大学 | warfarin-4-O-acetyl-LDV, synthesis, activity and application thereof |
| CN108976280A (en) * | 2017-05-30 | 2018-12-11 | 首都医科大学 | The amine-modified LDV of fat, synthesis, activity and application |
| CN108976283B (en) * | 2017-05-30 | 2021-12-03 | 首都医科大学 | 1, 1-dihydroxymethyl-tetrahydro-beta-carboline-3-formyl-GLDV, and synthesis, activity and application thereof |
| CN108976283A (en) * | 2017-05-30 | 2018-12-11 | 首都医科大学 | 1,1- dihydroxymethyl-tetrahydro-beta-carboline -3- formyl-GLDV, synthesis, activity and application |
| CN108976282B (en) * | 2017-06-01 | 2021-09-24 | 首都医科大学 | Fatty alcohol modified LDV derivatives, synthesis, activity and application thereof |
| CN108976281A (en) * | 2017-06-01 | 2018-12-11 | 首都医科大学 | The LDV derivative of fatty acid modifying, synthesis, activity and application |
| CN108976282A (en) * | 2017-06-01 | 2018-12-11 | 首都医科大学 | The LDV derivative of fatty alcohol modification, synthesis, activity and application |
| CN109111502A (en) * | 2017-06-23 | 2019-01-01 | 首都医科大学 | 1,1- dihydroxymethyl-tetrahydro-beta-carboline -3- formyl-GGPRP, synthesis, activity and application |
| CN109111502B (en) * | 2017-06-23 | 2022-04-22 | 首都医科大学 | 1, 1-dihydroxymethyl-tetrahydro-beta-carboline-3-formyl-GGPRP, and synthesis, activity and application thereof |
| CN110551176A (en) * | 2018-06-04 | 2019-12-10 | 首都医科大学 | LDV modified S, R-heptacyclic aldehyde, and synthesis, activity and application thereof |
| CN110577582A (en) * | 2018-06-08 | 2019-12-17 | 首都医科大学 | LDV modified heptacyclic aldehyde, synthesis, antithrombotic activity and application thereof |
| CN110577582B (en) * | 2018-06-08 | 2022-09-02 | 首都医科大学 | LDV modified heptacyclic aldehyde, synthesis, antithrombotic activity and application thereof |
| CN111995658A (en) * | 2019-05-27 | 2020-11-27 | 首都医科大学 | LDV (laser direct structuring) modified pentacyclic piperazinedione and preparation and application thereof |
| CN111995658B (en) * | 2019-05-27 | 2022-08-02 | 首都医科大学 | LDV (laser direct structuring) modified pentacyclic piperazinedione and preparation and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105315338A (en) | LDV-modified [beta]-carboline, and preparation, nano structure, activity and application thereof | |
| CN105273055A (en) | RGD tetrapeptide-modified beta-carboline, preparation, activity and application thereof | |
| CN105273054A (en) | YIGSR-modified beta-carboline, preparation, nano-structure, activity and application thereof | |
| CN103159828B (en) | 1-(4-hydroxy-3-methoxycarbonyl)-beta-carboline-3-formyl tryptophyl amino acid benzyl ester, and synthesis and application thereof | |
| CN105218634A (en) | The indoles quinolizine that YIGSR modifies, its preparation, nanostructure, active and application | |
| CN105218637A (en) | The indoles quinolizine that LPNISKP modifies, its preparation, nanostructure, active and application | |
| CN105218638A (en) | The indoles quinolizine that RGDS modifies, its preparation, nanostructure, active and application | |
| CN105884862B (en) | B-carboline acyl-tryptophan of RGD tetrapeptide modification, preparation, nanostructure, activity and application | |
| CN105315332A (en) | CIPPC-AA-OBzl, and preparation, nano structure, activity and application thereof | |
| CN105153277A (en) | Beta-carboline modified by KE as well as preparation, nanostructure, activity and application of the same | |
| CN103864890A (en) | Imidazolisopropylacetyltheaninecarbobenzoxypyridoindole, and preparation method, nanostructure and application thereof | |
| CN105218636A (en) | The β-carboline that LPNISKP modifies, its preparation, nanostructure, active and application | |
| CN105218635A (en) | The β-carboline that Trp-Trp-Trp pentapeptide is modified, its preparation, nanostructure, active and application | |
| CN105294835A (en) | LDV modified 5-fluorouracil, preparation therefor, nanostructure thereof, vigor thereof and application thereof | |
| CN105273053A (en) | Trp-Trp-Trp decapeptide modified beta-carboline, and preparation, nanometer structure, activity and application thereof | |
| CN114835897B (en) | PH sensitivity and active targeting functional material and preparation method and application thereof | |
| CN105315341A (en) | [Beta]-carboline modified by Trp-Trp-Trp hexapeptide, and preparation, nano structure, activity and application thereof | |
| CN105294836A (en) | LPNISKP modified 5-fluorouracil, preparation therefor, nanostructure thereof, activity thereof and application thereof | |
| CN112010855B (en) | Hexacyclic piperazinedione compounds, preparation, biological activity and application thereof | |
| CN104151304B (en) | A kind of triazole class compounds | |
| CN105273056A (en) | YIGSR-modified 5-fluorouracil, preparation, nano-structure, activity and application thereof | |
| CN105273046A (en) | Lys-Glu modified indoloquinolizine, preparation, nano-structure, activity and application thereof | |
| CN105315342A (en) | LDV-modified indolequinolizine, and preparation, nano structure, activity and application thereof | |
| CN105294834A (en) | Imidazo-pyridine-6-formyl-AA-OBzl, as well as synthesis, activities and application thereof | |
| CN108440577B (en) | Mixed copper-based complex and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160210 |